BeiGene | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

A Study of BGB-16673 Compared to Investigator’s Choice in Participants With Chronic Lymphocytic Leukemia Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Beigene Study ID

BGB-16673-302

ClinicalTrials.gov ID

NCT06846671

EudraCT Number

2024-518893-15-00

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents